A randomized, double-blind, placebo-controlled evaluation of the effects of tegaserod (6 mg b.i.d) on whole gut transit time in patients with chronic idiopathic constipation and dyspepsia

Trial Profile

A randomized, double-blind, placebo-controlled evaluation of the effects of tegaserod (6 mg b.i.d) on whole gut transit time in patients with chronic idiopathic constipation and dyspepsia

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Tegaserod (Primary)
  • Indications Constipation; Dyspepsia
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 24 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top